1. Targeting the β‐clamp in Helicobacter pylori with <scp>FDA</scp> ‐approved drugs reveals micromolar inhibition by diflunisal
- Author
-
Nilima Kumari, Preeti Pandey, Gunjan Gautam, Vijay Verma, Suman Kumar Dhar, and Samudrala Gourinath
- Subjects
0301 basic medicine ,Drug ,DNA Ligases ,Protein Conformation ,media_common.quotation_subject ,Drug Evaluation, Preclinical ,Biophysics ,Diflunisal ,Pharmacology ,Crystallography, X-Ray ,Biochemistry ,Inhibitory Concentration 50 ,03 medical and health sciences ,0302 clinical medicine ,Non-competitive inhibition ,Structural Biology ,Genetics ,medicine ,Enzyme Inhibitors ,Binding site ,Drug Approval ,Molecular Biology ,DNA Polymerase III ,media_common ,chemistry.chemical_classification ,Binding Sites ,Helicobacter pylori ,biology ,United States Food and Drug Administration ,Chemistry ,Cell Biology ,biology.organism_classification ,United States ,Anti-Bacterial Agents ,Molecular Docking Simulation ,030104 developmental biology ,Enzyme ,Drug development ,Prokaryotic DNA replication ,030220 oncology & carcinogenesis ,medicine.drug - Abstract
The β-clamp is the processivity-promoting factor for most of the enzymes in prokaryotic DNA replication; hence, it is a crucial drug target. In the present study, we investigated the β-clamp from Helicobacter pylori, aiming to seek potential drug molecules against this gastric-cancer-causing bacterium. An in silico screening of Food and Drug Administration (FDA) approved drugs against the H. pylori β-clamp, followed by its in vitro inhibition using a surface competition approach, yielded the drug diflunisal as a positive initial hit. Diflunisal inhibits the growth of H. pylori in the micromolar range. We determined the structure of diflunisal in complex with the β-clamp to show that the drug binds at subsite I, which is a protein-protein interaction site. Successful identification of FDA-approved molecules against H. pylori may lead to better and faster drug development.
- Published
- 2017